<sentence id="244" labeldrug="SEREVENT" section="34066-1">
<sentencetext>WARNING: ASTHMA-RELATED DEATH Long-acting beta2-adrenergic agonists (LABA), such as salmeterol, the active ingredient in SEREVENT DISKUS, as monotherapy (without inhaled corticosteroids [ICS]) increase the risk of asthma-related death.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="245" labeldrug="SEREVENT" section="34066-1">
<sentencetext>Data from a large placebo-controlled U.S. trial that compared the safety of salmeterol with placebo added to usual asthma therapy showed an increase in asthma-related deaths in subjects receiving salmeterol (13 deaths out of 13,176 subjects treated for 28 weeks on salmeterol versus 3 deaths out of 13,179 subjects on placebo).</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M12" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="246" labeldrug="SEREVENT" section="34066-1">
<sentencetext>Use of background ICS was not required in this study.</sentencetext>
</sentence>
<sentence id="247" labeldrug="SEREVENT" section="34066-1">
<sentencetext>When LABA are used in fixed-dose combination with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared with ICS alone.</sentencetext>
</sentence>
<sentence id="248" labeldrug="SEREVENT" section="34066-1">
<sentencetext>Use of SEREVENT DISKUS for the treatment of asthma as monotherapy without a concomitant ICS is contraindicated.</sentencetext>
</sentence>
<sentence id="249" labeldrug="SEREVENT" section="34066-1">
<sentencetext>Use SEREVENT DISKUS only as additional therapy for patients with asthma who are currently taking but are inadequately controlled on an ICS.</sentencetext>
</sentence>
<sentence id="250" labeldrug="SEREVENT" section="34066-1">
<sentencetext>Do not use SEREVENT DISKUS for patients whose asthma is adequately controlled on low- or medium-dose ICS.</sentencetext>
</sentence>
<sentence id="251" labeldrug="SEREVENT" section="34066-1">
<sentencetext>Pediatric and Adolescent Patients Available data from controlled clinical trials suggest that LABA as monotherapy increase the risk of asthma-related hospitalization in pediatric and adolescent patients.</sentencetext>
</sentence>
<sentence id="252" labeldrug="SEREVENT" section="34066-1">
<sentencetext>For pediatric and adolescent patients with asthma who require addition of a LABA to an ICS, a fixed-dose combination product containing both an ICS and a LABA should ordinarily be used to ensure adherence with both drugs.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="253" labeldrug="SEREVENT" section="34066-1">
<sentencetext>In cases where use of an ICS and a LABA is clinically indicated, appropriate steps must be taken to ensure adherence with both treatment components.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M12" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="254" labeldrug="SEREVENT" section="34066-1">
<sentencetext>If adherence cannot be assured, a fixed-dose combination product containing both an ICS and a LABA is recommended.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="255" labeldrug="SEREVENT" section="34066-1">
<sentencetext>WARNING: ASTHMA-RELATED DEATH See full prescribing information for complete boxed warning  Long-acting beta2-adrenergic agonists (LABA), such as salmeterol, the active in gre dient in SEREVENT DISKUS, as monotherapy (without inhaled corticosteroids [ICS]) increase the risk of asthma-related death.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M12" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="256" labeldrug="SEREVENT" section="34066-1">
<sentencetext>A U.S. trial showed an increase in asthma-related deaths in subjects receiving salmeterol (13 deaths out of 13,176 subjects treated for 28 weeks on salmeterol versus 3 out of 13,179 subjects on placebo).</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="257" labeldrug="SEREVENT" section="34066-1">
<sentencetext>Prescribe SEREVENT DISKUS only as additional therapy for patients with asthma who are currently taking but are inadequately controlled on an ICS.</sentencetext>
</sentence>
<sentence id="258" labeldrug="SEREVENT" section="34066-1">
<sentencetext>Available data from controlled clinical trials suggest that LABA as monotherapy increase the risk of asthma-related hospitalization in pediatric and adolescent patients.</sentencetext>
</sentence>
<sentence id="259" labeldrug="SEREVENT" section="34070-3">
<sentencetext>Use of SEREVENT DISKUS for the treatment of asthma without concomitant use of an ICS is contraindicated.</sentencetext>
</sentence>
<sentence id="260" labeldrug="SEREVENT" section="34070-3">
<sentencetext>The use of SEREVENT DISKUS is contraindicated in the following conditions: Primary treatment of status asthmaticus or other acute episodes of asthma or COPD where intensive measures are required Severe hypersensitivity to milk proteins or demonstrated hypersensitivity to salmeterol or any of the excipients Asthma: Without concomitant use of an ICS.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="261" labeldrug="SEREVENT" section="34070-3">
<sentencetext>Primary treatment of status asthmaticus or acute episodes of asthma or COPD requiring intensive measures.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="262" labeldrug="SEREVENT" section="34070-3">
<sentencetext>Severe hypersensitivity to milk proteins or demonstrated hypersensitivity to salmeterol or any of the excipients.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M12" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="263" labeldrug="SEREVENT" section="34068-7">
<sentencetext>SEREVENT DISKUS should be administered by the orally inhaled route only.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="264" labeldrug="SEREVENT" section="34068-7">
<sentencetext>More frequent administration or a greater number of inhalations (more than 1 inhalation twice daily) is not recommended as some patients are more likely to experience adverse effects.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="265" labeldrug="SEREVENT" section="34068-7">
<sentencetext>Patients using SEREVENT DISKUS should not use additional LABA for any reason.</sentencetext>
</sentence>
<sentence id="266" labeldrug="SEREVENT" section="34068-7">
<sentencetext>Treatment of asthma in patients aged 4 years and older: 1 inhalation twice daily in addition to concomitant treatment with an ICS.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="267" labeldrug="SEREVENT" section="34068-7">
<sentencetext>EIB: 1 inhalation at least 30 minutes before exercise.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="268" labeldrug="SEREVENT" section="34068-7">
<sentencetext>Maintenance treatment of bronchospasm associated with COPD: 1 inhalation twice daily.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="269" labeldrug="SEREVENT" section="34068-7">
<sentencetext>LABA, such as salmeterol, the active ingredient in SEREVENT DISKUS, as monotherapy (without ICS) increase the risk of asthma-related death.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="270" labeldrug="SEREVENT" section="34068-7">
<sentencetext>Because of this risk, use of SEREVENT DISKUS for the treatment of asthma without concomitant use of an ICS is contraindicated.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="271" labeldrug="SEREVENT" section="34068-7">
<sentencetext>For patients with asthma younger than 18 years who require addition of a LABA to an ICS, a fixed-dose combination product containing both an ICS and a LABA should ordinarily be used to ensure adherence with both drugs.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M12" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="272" labeldrug="SEREVENT" section="34068-7">
<sentencetext>In cases where use of a separate ICS and a LABA is clinically indicated, appropriate steps must be taken to ensure adherence with both treatment components.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="273" labeldrug="SEREVENT" section="34068-7">
<sentencetext>For bronchodilatation and prevention of symptoms of asthma, including the symptoms of nocturnal asthma, the usual dosage for adults and children aged 4 years and older is 1 inhalation (50 mcg) twice daily, approximately 12 hours apart.</sentencetext>
</sentence>
<sentence id="274" labeldrug="SEREVENT" section="34068-7">
<sentencetext>If a previously effective dosage regimen fails to provide the usual response, medical advice should be sought immediately as this is often a sign of destabilization of asthma.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="275" labeldrug="SEREVENT" section="34068-7">
<sentencetext>Under these circumstances, the therapeutic regimen should be reevaluated.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="276" labeldrug="SEREVENT" section="34068-7">
<sentencetext>If symptoms arise in the period between doses, an inhaled, short-acting beta2-agonist should be taken for immediate relief.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M12" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="277" labeldrug="SEREVENT" section="34068-7">
<sentencetext>Use of SEREVENT DISKUS as a single agent for the prevention of EIB may be clinically indicated in patients who do not have persistent asthma.</sentencetext>
</sentence>
<sentence id="278" labeldrug="SEREVENT" section="34068-7">
<sentencetext>In patients with persistent asthma, use of SEREVENT DISKUS for the prevention of EIB may be clinically indicated, but the treatment of asthma should include an ICS.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="279" labeldrug="SEREVENT" section="34068-7">
<sentencetext>One inhalation of SEREVENT DISKUS at least 30 minutes before exercise has been shown to protect patients against EIB.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="280" labeldrug="SEREVENT" section="34068-7">
<sentencetext>When used intermittently as needed for prevention of EIB, this protection may last up to 9 hours in adults and adolescents and up to 12 hours in patients aged 4 to 11 years.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="281" labeldrug="SEREVENT" section="34068-7">
<sentencetext>Additional doses of SEREVENT should not be used for 12 hours after the administration of this drug.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="282" labeldrug="SEREVENT" section="34068-7">
<sentencetext>Patients who are receiving SEREVENT DISKUS twice daily should not use additional SEREVENT for prevention of EIB.</sentencetext>
</sentence>
<sentence id="283" labeldrug="SEREVENT" section="34068-7">
<sentencetext>For maintenance treatment of bronchospasm associated with COPD (including chronic bronchitis and emphysema), the dosage for adults is 1 inhalation (50 mcg) twice daily approximately 12 hours apart.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="284" labeldrug="SEREVENT" section="34073-7">
<sentencetext>Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): Use not recommended.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="285" labeldrug="SEREVENT" section="34073-7">
<sentencetext>May increase risk of cardiovascular effects.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="286" labeldrug="SEREVENT" section="34073-7">
<sentencetext>Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="287" labeldrug="SEREVENT" section="34073-7">
<sentencetext>May potentiate effect of salmeterol on vascular system.</sentencetext>
</sentence>
<sentence id="288" labeldrug="SEREVENT" section="34073-7">
<sentencetext>Beta-blockers: Use with caution.</sentencetext>
</sentence>
<sentence id="289" labeldrug="SEREVENT" section="34073-7">
<sentencetext>May block bronchodilatory effects of beta-agonists and produce severe bronchospasm.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="290" labeldrug="SEREVENT" section="34073-7">
<sentencetext>Electrocardiographic changes and/or hypokalemia associated with non–potassium-sparing diuretics may worsen with concomitant beta-agonists.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="291" labeldrug="SEREVENT" section="34073-7">
<sentencetext>Salmeterol is a substrate of CYP3A4.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="292" labeldrug="SEREVENT" section="34073-7">
<sentencetext>The use of strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, ketoconazole, telithromycin) with SEREVENT DISKUS is not recommended because increased cardiovascular adverse effects may occur.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M12" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="293" labeldrug="SEREVENT" section="34073-7">
<sentencetext>In a drug interaction trial in 20 healthy subjects, coadministration of inhaled salmeterol (50 mcg twice daily) and oral ketoconazole (400 mg once daily) for 7 days resulted in greater systemic exposure to salmeterol (AUC increased 16-fold and Cmax increased 1.4-fold).</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="294" labeldrug="SEREVENT" section="34073-7">
<sentencetext>Three (3) subjects were withdrawn due to beta2-agonist side effects (2 with prolonged QTc and 1 with palpitations and sinus tachycardia).</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M12" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="295" labeldrug="SEREVENT" section="34073-7">
<sentencetext>Although there was no statistical effect on the mean QTc, coadministration of salmeterol and ketoconazole was associated with more frequent increases in QTc duration compared with salmeterol and placebo administration.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="296" labeldrug="SEREVENT" section="34073-7">
<sentencetext>SEREVENT DISKUS should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, because the action of salmeterol on the vascular system may be potentiated by these agents.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M12" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="297" labeldrug="SEREVENT" section="34073-7">
<sentencetext>Beta-blockers not only block the pulmonary effect of beta-agonists, such as salmeterol, but may also produce severe bronchospasm in patients with asthma or COPD.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="298" labeldrug="SEREVENT" section="34073-7">
<sentencetext>Therefore, patients with asthma or COPD should not normally be treated with beta-blockers.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M12" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="299" labeldrug="SEREVENT" section="34073-7">
<sentencetext>However, under certain circumstances, there may be no acceptable alternatives to the use of beta-adrenergic blocking agents for these patients; cardioselective beta-blockers could be considered, although they should be administered with caution.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="300" labeldrug="SEREVENT" section="34073-7">
<sentencetext>The ECG changes and/or hypokalemia that may result from the administration of non–potassium-sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="301" labeldrug="SEREVENT" section="34073-7">
<sentencetext>Although the clinical significance of these effects is not known, caution is advised in the coadministration of SEREVENT DISKUS with non–potassium-sparing diuretics.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="302" labeldrug="SEREVENT" section="43685-7">
<sentencetext>LABA as monotherapy (without ICS) for asthma increase the risk of asthma-related death and asthma-related hospitalizations.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="303" labeldrug="SEREVENT" section="43685-7">
<sentencetext>Prescribe for asthma only as concomitant therapy with an inhaled corticosteroid.</sentencetext>
</sentence>
<sentence id="304" labeldrug="SEREVENT" section="43685-7">
<sentencetext>Do not initiate in acutely deteriorating asthma or COPD.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="305" labeldrug="SEREVENT" section="43685-7">
<sentencetext>Not a substitute for corticosteroids.</sentencetext>
</sentence>
<sentence id="306" labeldrug="SEREVENT" section="43685-7">
<sentencetext>Patients with asthma must take a concomitant ICS.</sentencetext>
</sentence>
<sentence id="307" labeldrug="SEREVENT" section="43685-7">
<sentencetext>Do not use in combination with an additional medicine containing a LABA because of risk of overdose.</sentencetext>
</sentence>
<sentence id="308" labeldrug="SEREVENT" section="43685-7">
<sentencetext>If paradoxical bronchospasm occurs, discontinue SEREVENT DISKUS and institute alternative therapy.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="309" labeldrug="SEREVENT" section="43685-7">
<sentencetext>Use with caution in patients with cardiovascular or central nervous system disorders because of beta-adrenergic stimulation.</sentencetext>
</sentence>
<sentence id="310" labeldrug="SEREVENT" section="43685-7">
<sentencetext>Use with caution in patients with convulsive disorders, thyrotoxicosis, diabetes mellitus, and ketoacidosis.</sentencetext>
</sentence>
<sentence id="311" labeldrug="SEREVENT" section="43685-7">
<sentencetext>Be alert to hypokalemia and hyperglycemia.</sentencetext>
</sentence>
<sentence id="312" labeldrug="SEREVENT" section="43685-7">
<sentencetext>When LABA are used in fixed‑dose combination with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared with ICS alone.</sentencetext>
</sentence>
<sentence id="313" labeldrug="SEREVENT" section="43685-7">
<sentencetext>The Salmeterol Multicenter Asthma Research Trial (SMART) was a large 28-week placebo-controlled U.S. trial comparing the safety of salmeterol (SEREVENT Inhalation Aerosol) with placebo, each added to usual asthma therapy, that showed an increase in asthma-related deaths in subjects receiving salmeterol.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="314" labeldrug="SEREVENT" section="43685-7">
<sentencetext>Given the similar basic mechanisms of action of beta2-agonists, the findings seen in the SMART trial are considered a class effect.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="315" labeldrug="SEREVENT" section="43685-7">
<sentencetext>A 16-week clinical trial performed in the United Kingdom, the Salmeterol Nationwide Surveillance (SNS) trial, showed results similar to the SMART trial.</sentencetext>
</sentence>
<sentence id="316" labeldrug="SEREVENT" section="43685-7">
<sentencetext>In the SNS trial, the rate of asthma-related death was numerically, though not statistically significantly, greater in subjects with asthma treated with salmeterol (42 mcg twice daily) than those treated with albuterol (180 mcg 4 times daily) added to usual asthma therapy.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="317" labeldrug="SEREVENT" section="43685-7">
<sentencetext>The SNS and SMART trials enrolled subjects with asthma.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="318" labeldrug="SEREVENT" section="43685-7">
<sentencetext>Available data do not suggest an increased risk of death with use of LABA in patients with COPD.</sentencetext>
</sentence>
<sentence id="319" labeldrug="SEREVENT" section="43685-7">
<sentencetext>SEREVENT DISKUS should not be initiated in patients during rapidly deteriorating or potentially life-threatening episodes of asthma or COPD.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M12" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M13" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M14" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M15" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="320" labeldrug="SEREVENT" section="43685-7">
<sentencetext>SEREVENT DISKUS has not been studied in subjects with acutely deteriorating asthma or COPD.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="321" labeldrug="SEREVENT" section="43685-7">
<sentencetext>The initiation of SEREVENT DISKUS in this setting is not appropriate.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="322" labeldrug="SEREVENT" section="43685-7">
<sentencetext>Serious acute respiratory events, including fatalities, have been reported when salmeterol has been initiated in patients with significantly worsening or acutely deteriorating asthma.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="323" labeldrug="SEREVENT" section="43685-7">
<sentencetext>In most cases, these have occurred in patients with severe asthma (e.g., patients with a history of corticosteroid dependence, low pulmonary function, intubation, mechanical ventilation, frequent hospitalizations, previous life-threatening acute asthma exacerbations) and in some patients with acutely deteriorating asthma (e.g., patients with significantly increasing symptoms; increasing need for inhaled, short-acting beta2-agonists; decreasing response to usual medications; increasing need for systemic corticosteroids; recent emergency room visits; deteriorating lung function).</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M12" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M13" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M14" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M15" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="324" labeldrug="SEREVENT" section="43685-7">
<sentencetext>However, these events have occurred in a few patients with less severe asthma as well.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="325" labeldrug="SEREVENT" section="43685-7">
<sentencetext>It was not possible from these reports to determine whether salmeterol contributed to these events.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M12" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="326" labeldrug="SEREVENT" section="43685-7">
<sentencetext>Increasing use of inhaled, short-acting beta2-agonists is a marker of deteriorating asthma.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="327" labeldrug="SEREVENT" section="43685-7">
<sentencetext>In this situation, the patient requires immediate reevaluation with reassessment of the treatment regimen, giving special consideration to the possible need for adding additional ICS or initiating systemic corticosteroids.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="328" labeldrug="SEREVENT" section="43685-7">
<sentencetext>Patients should not use more than 1 inhalation twice daily of SEREVENT DISKUS.</sentencetext>
</sentence>
<sentence id="329" labeldrug="SEREVENT" section="43685-7">
<sentencetext>SEREVENT DISKUS should not be used for the relief of acute symptoms, i.e., as rescue therapy for the treatment of acute episodes of bronchospasm.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="330" labeldrug="SEREVENT" section="43685-7">
<sentencetext>An inhaled, short-acting beta2-agonist, not SEREVENT DISKUS, should be used to relieve acute symptoms such as shortness of breath.</sentencetext>
</sentence>
<sentence id="331" labeldrug="SEREVENT" section="43685-7">
<sentencetext>When prescribing SEREVENT DISKUS, the healthcare provider should also prescribe an inhaled, short-acting beta2-agonist (e.g., albuterol) for treatment of acute symptoms.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="332" labeldrug="SEREVENT" section="43685-7">
<sentencetext>When beginning treatment with SEREVENT DISKUS, patients who have been taking oral or inhaled, short-acting beta2-agonists on a regular basis (e.g., 4 times a day) should be instructed to discontinue the regular use of these drugs.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M12" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="333" labeldrug="SEREVENT" section="43685-7">
<sentencetext>There are no data demonstrating that SEREVENT DISKUS has a clinical anti-inflammatory effect such as that associated with corticosteroids.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="334" labeldrug="SEREVENT" section="43685-7">
<sentencetext>When initiating and throughout treatment with SEREVENT DISKUS in patients receiving oral or ICS for treatment of asthma, patients must continue taking a suitable dosage of corticosteroids to maintain clinical stability even if they feel better as a result of initiating SEREVENT DISKUS.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="335" labeldrug="SEREVENT" section="43685-7">
<sentencetext>Any change in corticosteroid dosage should be made ONLY after clinical evaluation.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="336" labeldrug="SEREVENT" section="43685-7">
<sentencetext>SEREVENT DISKUS should not be used more often than recommended, at higher doses than recommended, or in conjunction with other medicines containing LABA, as an overdose may result.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="337" labeldrug="SEREVENT" section="43685-7">
<sentencetext>Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="338" labeldrug="SEREVENT" section="43685-7">
<sentencetext>Patients using SEREVENT DISKUS should not use another medicine containing a LABA (e.g., formoterol fumarate, arformoterol tartrate, indacaterol) for any reason.</sentencetext>
</sentence>
<sentence id="339" labeldrug="SEREVENT" section="43685-7">
<sentencetext>As with other inhaled medicines, SEREVENT DISKUS can produce paradoxical bronchospasm, which may be life threatening.</sentencetext>
</sentence>
<sentence id="340" labeldrug="SEREVENT" section="43685-7">
<sentencetext>If paradoxical bronchospasm occurs following dosing with SEREVENT DISKUS, it should be treated immediately with an inhaled, short-acting bronchodilator; SEREVENT DISKUS should be discontinued immediately; and alternative therapy should be instituted.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="341" labeldrug="SEREVENT" section="43685-7">
<sentencetext>Upper airway symptoms of laryngeal spasm, irritation, or swelling, such as stridor and choking, have been reported in patients receiving SEREVENT DISKUS.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="342" labeldrug="SEREVENT" section="43685-7">
<sentencetext>Excessive beta-adrenergic stimulation has been associated with seizures, angina, hypertension or hypotension, tachycardia with rates up to 200 beats/min, arrhythmias, nervousness, headache, tremor, palpitation, nausea, dizziness, fatigue, malaise, and insomnia.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M12" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="343" labeldrug="SEREVENT" section="43685-7">
<sentencetext>Therefore, SEREVENT DISKUS, like all products containing sympathomimetic amines, should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="344" labeldrug="SEREVENT" section="43685-7">
<sentencetext>Salmeterol can produce a clinically significant cardiovascular effect in some patients as measured by pulse rate, blood pressure, and/or symptoms.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="345" labeldrug="SEREVENT" section="43685-7">
<sentencetext>Although such effects are uncommon after administration of salmeterol at recommended doses, if they occur, the drug may need to be discontinued.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="346" labeldrug="SEREVENT" section="43685-7">
<sentencetext>In addition, beta-agonists have been reported to produce electrocardiogram (ECG) changes, such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="347" labeldrug="SEREVENT" section="43685-7">
<sentencetext>The clinical significance of these findings is unknown.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="348" labeldrug="SEREVENT" section="43685-7">
<sentencetext>Large doses of inhaled or oral salmeterol (12 to 20 times the recommended dose) have been associated with clinically significant prolongation of the QTc interval, which has the potential for producing ventricular arrhythmias.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M12" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="349" labeldrug="SEREVENT" section="43685-7">
<sentencetext>Fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="350" labeldrug="SEREVENT" section="43685-7">
<sentencetext>Immediate hypersensitivity reactions (e.g., urticaria, angioedema, rash, bronchospasm, hypotension), including anaphylaxis, may occur after administration of SEREVENT DISKUS.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="351" labeldrug="SEREVENT" section="43685-7">
<sentencetext>There have been reports of anaphylactic reactions in patients with severe milk protein allergy after inhalation of powder products containing lactose; therefore, patients with severe milk protein allergy should not use SEREVENT DISKUS.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="352" labeldrug="SEREVENT" section="43685-7">
<sentencetext>The use of strong cytochrome P450 3A4 (CYP3A4) inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, ketoconazole, telithromycin) with SEREVENT DISKUS is not recommended because increased cardiovascular adverse effects may occur.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M12" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="353" labeldrug="SEREVENT" section="43685-7">
<sentencetext>SEREVENT DISKUS, like all medicines containing sympathomimetic amines, should be used with caution in patients with convulsive disorders or thyrotoxicosis and in those who are unusually responsive to sympathomimetic amines.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="354" labeldrug="SEREVENT" section="43685-7">
<sentencetext>Doses of the related beta2-adrenoceptor agonist albuterol, when administered intravenously, have been reported to aggravate preexisting diabetes mellitus and ketoacidosis.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="355" labeldrug="SEREVENT" section="43685-7">
<sentencetext>Beta-adrenergic agonist medicines may produce significant hypokalemia in some patients, possibly through intracellular shunting, which has the potential to produce adverse cardiovascular effects.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="356" labeldrug="SEREVENT" section="43685-7">
<sentencetext>The decrease in serum potassium is usually transient, not requiring supplementation.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="357" labeldrug="SEREVENT" section="43685-7">
<sentencetext>Clinically significant and dose-related changes in blood glucose and/or serum potassium were seen infrequently during clinical trials with SEREVENT DISKUS at recommended doses.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="358" labeldrug="SEREVENT" section="34090-1">
<sentencetext>In vitro studies show salmeterol to be at least 50 times more selective for beta2-adrenoceptors than albuterol.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M12" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="359" labeldrug="SEREVENT" section="34090-1">
<sentencetext>Although beta2-adrenoceptors are the predominant adrenergic receptors in bronchial smooth muscle and beta1-adrenoceptors are the predominant receptors in the heart, there are also beta2-adrenoceptors in the human heart comprising 10% to 50% of the total beta-adrenoceptors.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="360" labeldrug="SEREVENT" section="34090-1">
<sentencetext>The precise function of these receptors has not been established, but their presence raises the possibility that even selective beta2-agonists may have cardiac effects.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="361" labeldrug="SEREVENT" section="34090-1">
<sentencetext>The pharmacologic effects of beta2-adrenoceptor agonist drugs, including salmeterol, are at least in part attributable to stimulation of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3′,5′-adenosine monophosphate (cyclic AMP).</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M12" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="362" labeldrug="SEREVENT" section="34090-1">
<sentencetext>Increased cyclic AMP levels cause relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M12" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="363" labeldrug="SEREVENT" section="34090-1">
<sentencetext>In vitro tests show that salmeterol is a potent and long-lasting inhibitor of the release of mast cell mediators, such as histamine, leukotrienes, and prostaglandin D2, from human lung.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M12" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="364" labeldrug="SEREVENT" section="34090-1">
<sentencetext>Salmeterol inhibits histamine-induced plasma protein extravasation and inhibits platelet-activating factor–induced eosinophil accumulation in the lungs of guinea pigs when administered by the inhaled route.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M12" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="365" labeldrug="SEREVENT" section="34090-1">
<sentencetext>In humans, single doses of salmeterol administered via inhalation aerosol attenuate allergen-induced bronchial hyper-responsiveness.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M12" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="366" labeldrug="SEREVENT" section="34090-1">
<sentencetext>Inhaled salmeterol, like other beta-adrenergic agonist drugs, can produce dose-related cardiovascular effects and effects on blood glucose and/or serum potassium.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="367" labeldrug="SEREVENT" section="34090-1">
<sentencetext>The cardiovascular effects (heart rate, blood pressure) associated with salmeterol inhalation aerosol occur with similar frequency, and are of similar type and severity, as those noted following albuterol administration.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M12" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="368" labeldrug="SEREVENT" section="34090-1">
<sentencetext>The effects of rising inhaled doses of salmeterol and standard inhaled doses of albuterol were studied in volunteers and in subjects with asthma.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="369" labeldrug="SEREVENT" section="34090-1">
<sentencetext>Salmeterol doses up to 84 mcg administered as inhalation aerosol resulted in heart rate increases of 3 to 16 beats/min, about the same as albuterol dosed at 180 mcg by inhalation aerosol (4 to 10 beats/min).</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M12" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="370" labeldrug="SEREVENT" section="34090-1">
<sentencetext>Adult and adolescent subjects receiving 50-mcg doses of salmeterol inhalation powder (n = 60) underwent continuous electrocardiographic monitoring during two 12-hour periods after the first dose and after 1 month of therapy, and no clinically significant dysrhythmias were noted.</sentencetext>
</sentence>
<sentence id="371" labeldrug="SEREVENT" section="34090-1">
<sentencetext>Also, pediatric patients receiving 50-mcg doses of salmeterol inhalation powder (n = 67) underwent continuous electrocardiographic monitoring during two 12-hour periods after the first dose and after 3 months of therapy, and no clinically significant dysrhythmias were noted.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="372" labeldrug="SEREVENT" section="34090-1">
<sentencetext>In 24-week clinical studies in patients with COPD, the incidence of clinically significant abnormalities on the predose ECGs at Weeks 12 and 24 in patients who received salmeterol 50 mcg was not different compared with placebo.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M12" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="373" labeldrug="SEREVENT" section="34090-1">
<sentencetext>No effect of treatment with salmeterol 50 mcg was observed on pulse rate and systolic and diastolic blood pressure in a subset of patients with COPD who underwent 12-hour serial vital sign measurements after the first dose (n = 91) and after 12 weeks of therapy (n = 74).</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M12" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="374" labeldrug="SEREVENT" section="34090-1">
<sentencetext>Median changes from baseline in pulse rate and systolic and diastolic blood pressure were similar for patients receiving either salmeterol or placebo.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="375" labeldrug="SEREVENT" section="34090-1">
<sentencetext>Concomitant Use of SEREVENT DISKUS with Other Respiratory Medications Short-acting Beta2-agonists: In two 12-week repetitive-dose clinical trials in adult and adolescent subjects with asthma (N = 149), the mean daily need for additional beta2-agonist in subjects using SEREVENT DISKUS was approximately 1½ inhalations/day.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="376" labeldrug="SEREVENT" section="34090-1">
<sentencetext>Twenty-six percent (26%) of the subjects in these trials used between 8 and 24 inhalations of short-acting beta-agonist per day on 1 or more occasions.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="377" labeldrug="SEREVENT" section="34090-1">
<sentencetext>Nine percent (9%) of the subjects in these trials averaged over 4 inhalations/day over the course of the 12-week trials.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="378" labeldrug="SEREVENT" section="34090-1">
<sentencetext>No increase in frequency of cardiovascular events was observed among the 3 subjects who averaged 8 to 11 inhalations/day; however, the safety of concomitant use of more than 8 inhalations/day of short-acting beta2-agonist with SEREVENT DISKUS has not been established.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="379" labeldrug="SEREVENT" section="34090-1">
<sentencetext>In 29 subjects who experienced worsening of asthma while receiving SEREVENT DISKUS during these trials, albuterol therapy administered via either nebulizer or inhalation aerosol (1 dose in most cases) led to improvement in FEV1 and no increase in occurrence of cardiovascular adverse events.</sentencetext>
</sentence>
<sentence id="380" labeldrug="SEREVENT" section="34090-1">
<sentencetext>In 2 clinical trials in subjects with COPD, the mean daily need for additional beta2-agonist for subjects using SEREVENT DISKUS was approximately 4 inhalations/day.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M12" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="381" labeldrug="SEREVENT" section="34090-1">
<sentencetext>Twenty-four percent (24%) of subjects using SEREVENT DISKUS averaged 6 or more inhalations of albuterol per day over the course of the 24-week trials.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="382" labeldrug="SEREVENT" section="34090-1">
<sentencetext>No increase in frequency of cardiovascular adverse reactions was observed among subjects who averaged 6 or more inhalations per day.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="383" labeldrug="SEREVENT" section="34090-1">
<sentencetext>Methylxanthines: The concurrent use of intravenously or orally administered methylxanthines (e.g., aminophylline, theophylline) by subjects receiving salmeterol has not been completely evaluated.</sentencetext>
</sentence>
<sentence id="384" labeldrug="SEREVENT" section="34090-1">
<sentencetext>In 1 clinical trial in subjects with asthma, 87 subjects receiving SEREVENT Inhalation Aerosol 42 mcg twice daily concurrently with a theophylline product had adverse event rates similar to those in 71 subjects receiving SEREVENT Inhalation Aerosol without theophylline.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M12" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="385" labeldrug="SEREVENT" section="34090-1">
<sentencetext>Resting heart rates were slightly higher in the subjects on theophylline but were little affected by therapy with SEREVENT Inhalation Aerosol.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="386" labeldrug="SEREVENT" section="34090-1">
<sentencetext>In 2 clinical trials in subjects with COPD, 39 subjects receiving SEREVENT DISKUS concurrently with a theophylline product had adverse event rates similar to those in 302 subjects receiving SEREVENT DISKUS without theophylline.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="387" labeldrug="SEREVENT" section="34090-1">
<sentencetext>Based on the available data, the concomitant administration of methylxanthines with SEREVENT DISKUS did not alter the observed adverse event profile.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="388" labeldrug="SEREVENT" section="34090-1">
<sentencetext>Cromoglycate: In clinical trials, inhaled cromolyn sodium did not alter the safety profile of salmeterol when administered concurrently.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="389" labeldrug="SEREVENT" section="34090-1">
<sentencetext>Salmeterol xinafoate, an ionic salt, dissociates in solution so that the salmeterol and 1-hydroxy-2-naphthoic acid (xinafoate) moieties are absorbed, distributed, metabolized, and eliminated independently.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="390" labeldrug="SEREVENT" section="34090-1">
<sentencetext>Salmeterol acts locally in the lung; therefore, plasma levels do not predict therapeutic effect.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="391" labeldrug="SEREVENT" section="34090-1">
<sentencetext>Absorption Because of the small therapeutic dose, systemic levels of salmeterol are low or undetectable after inhalation of recommended doses (50 mcg of salmeterol inhalation powder twice daily).</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="392" labeldrug="SEREVENT" section="34090-1">
<sentencetext>Following chronic administration of an inhaled dose of 50 mcg of salmeterol inhalation powder twice daily, salmeterol was detected in plasma within 5 to 45 minutes in 7 subjects with asthma; plasma concentrations were very low, with mean peak concentrations of 167 pg/mL at 20 minutes and no accumulation with repeated doses.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="393" labeldrug="SEREVENT" section="34090-1">
<sentencetext>Distribution The percentage of salmeterol bound to human plasma proteins averages 96% in vitro over the concentration range of 8 to 7,722 ng of salmeterol base per milliliter, much higher concentrations than those achieved following therapeutic doses of salmeterol.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="394" labeldrug="SEREVENT" section="34090-1">
<sentencetext>Metabolism Salmeterol base is extensively metabolized by hydroxylation, with subsequent elimination predominantly in the feces.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M12" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="395" labeldrug="SEREVENT" section="34090-1">
<sentencetext>No significant amount of unchanged salmeterol base was detected in either urine or feces.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="396" labeldrug="SEREVENT" section="34090-1">
<sentencetext>An in vitro study using human liver microsomes showed that salmeterol is extensively metabolized to α-hydroxysalmeterol (aliphatic oxidation) by CYP3A4.</sentencetext>
</sentence>
<sentence id="397" labeldrug="SEREVENT" section="34090-1">
<sentencetext>Ketoconazole, a strong inhibitor of CYP3A4, essentially completely inhibited the formation of α-hydroxysalmeterol in vitro.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="398" labeldrug="SEREVENT" section="34090-1">
<sentencetext>Elimination In 2 healthy adult subjects who received 1 mg of radiolabeled salmeterol (as salmeterol xinafoate) orally, approximately 25% and 60% of the radiolabeled salmeterol was eliminated in urine and feces, respectively, over a period of 7 days.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M12" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="399" labeldrug="SEREVENT" section="34090-1">
<sentencetext>The terminal elimination half-life was about 5.5 hours (1 volunteer only).</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="400" labeldrug="SEREVENT" section="34090-1">
<sentencetext>The xinafoate moiety has no apparent pharmacologic activity.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="401" labeldrug="SEREVENT" section="34090-1">
<sentencetext>The xinafoate moiety is highly protein bound (&gt;99%) and has a long elimination half-life of 11 days.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="402" labeldrug="SEREVENT" section="34090-1">
<sentencetext>Drug Interaction Studies Inhibitors of Cytochrome P450 3A4: Ketoconazole: In a placebo-controlled crossover drug interaction trial in 20 healthy male and female subjects, coadministration of salmeterol (50 mcg twice daily) and the strong CYP3A4 inhibitor ketoconazole (400 mg once daily) for 7 days resulted in a significant increase in plasma salmeterol exposure as determined by a 16-fold increase in AUC (ratio with and without ketoconazole 15.76 [90% CI: 10.66, 23.31]) mainly due to increased bioavailability of the swallowed portion of the dose.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M12" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M13" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M14" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="403" labeldrug="SEREVENT" section="34090-1">
<sentencetext>Peak plasma salmeterol concentrations were increased by 1.4-fold (90% CI: 1.23, 1.68).</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="404" labeldrug="SEREVENT" section="34090-1">
<sentencetext>Three (3) out of 20 subjects (15%) were withdrawn from salmeterol and ketoconazole coadministration due to beta-agonist–mediated systemic effects (2 with QTc prolongation and 1 with palpitations and sinus tachycardia).</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M12" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M13" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="405" labeldrug="SEREVENT" section="34090-1">
<sentencetext>Coadministration of salmeterol and ketoconazole did not result in a clinically significant effect on mean heart rate, mean blood potassium, or mean blood glucose.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="406" labeldrug="SEREVENT" section="34090-1">
<sentencetext>Erythromycin: In a repeat-dose trial in 13 healthy subjects, concomitant administration of erythromycin (a moderate CYP3A4 inhibitor) and salmeterol inhalation aerosol resulted in a 40% increase in salmeterol Cmax at steady state (ratio with and without erythromycin 1.4 [90% CI: 0.96, 2.03], P = 0.12), a 3.6-beat/min increase in heart rate ([95% CI: 0.19, 7.03], P&lt;0.04), a 5.8-msec increase in QTc interval ([95% CI: -6.14, 17.77], P = 0.34), and no change in plasma potassium.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M12" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M13" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M14" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M15" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="244" labeldrug="SEREVENT" section="34066-1">
<sentencetext>WARNING: ASTHMA-RELATED DEATH Long-acting beta2-adrenergic agonists (LABA), such as salmeterol, the active ingredient in SEREVENT DISKUS, as monotherapy (without inhaled corticosteroids [ICS]) increase the risk of asthma-related death.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M13" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="245" labeldrug="SEREVENT" section="34066-1">
<sentencetext>Data from a large placebo-controlled U.S. trial that compared the safety of salmeterol with placebo added to usual asthma therapy showed an increase in asthma-related deaths in subjects receiving salmeterol (13 deaths out of 13,176 subjects treated for 28 weeks on salmeterol versus 3 deaths out of 13,179 subjects on placebo).</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M13" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M12" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="246" labeldrug="SEREVENT" section="34066-1">
<sentencetext>Use of background ICS was not required in this study.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
</sentence>
<sentence id="247" labeldrug="SEREVENT" section="34066-1">
<sentencetext>When LABA are used in fixed-dose combination with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared with ICS alone.</sentencetext>
</sentence>
<sentence id="248" labeldrug="SEREVENT" section="34066-1">
<sentencetext>Use of SEREVENT DISKUS for the treatment of asthma as monotherapy without a concomitant ICS is contraindicated.</sentencetext>
</sentence>
<sentence id="249" labeldrug="SEREVENT" section="34066-1">
<sentencetext>Use SEREVENT DISKUS only as additional therapy for patients with asthma who are currently taking but are inadequately controlled on an ICS.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
</sentence>
<sentence id="250" labeldrug="SEREVENT" section="34066-1">
<sentencetext>Do not use SEREVENT DISKUS for patients whose asthma is adequately controlled on low- or medium-dose ICS.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M13" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M14" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M15" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M16" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M17" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M18" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M19" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M110" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M111" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M112" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M113" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M114" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M115" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M116" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M117" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M118" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M119" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M120" span="2 3" str="Hello" type="Trigger"></mention>
</sentence>
<sentence id="251" labeldrug="SEREVENT" section="34066-1">
<sentencetext>Pediatric and Adolescent Patients Available data from controlled clinical trials suggest that LABA as monotherapy increase the risk of asthma-related hospitalization in pediatric and adolescent patients.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
</sentence>
<sentence id="252" labeldrug="SEREVENT" section="34066-1">
<sentencetext>For pediatric and adolescent patients with asthma who require addition of a LABA to an ICS, a fixed-dose combination product containing both an ICS and a LABA should ordinarily be used to ensure adherence with both drugs.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M13" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="253" labeldrug="SEREVENT" section="34066-1">
<sentencetext>In cases where use of an ICS and a LABA is clinically indicated, appropriate steps must be taken to ensure adherence with both treatment components.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M13" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M14" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M12" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="254" labeldrug="SEREVENT" section="34066-1">
<sentencetext>If adherence cannot be assured, a fixed-dose combination product containing both an ICS and a LABA is recommended.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="255" labeldrug="SEREVENT" section="34066-1">
<sentencetext>WARNING: ASTHMA-RELATED DEATH See full prescribing information for complete boxed warning  Long-acting beta2-adrenergic agonists (LABA), such as salmeterol, the active in gre dient in SEREVENT DISKUS, as monotherapy (without inhaled corticosteroids [ICS]) increase the risk of asthma-related death.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M13" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M14" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M15" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M16" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M12" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="256" labeldrug="SEREVENT" section="34066-1">
<sentencetext>A U.S. trial showed an increase in asthma-related deaths in subjects receiving salmeterol (13 deaths out of 13,176 subjects treated for 28 weeks on salmeterol versus 3 out of 13,179 subjects on placebo).</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="257" labeldrug="SEREVENT" section="34066-1">
<sentencetext>Prescribe SEREVENT DISKUS only as additional therapy for patients with asthma who are currently taking but are inadequately controlled on an ICS.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
</sentence>
<sentence id="258" labeldrug="SEREVENT" section="34066-1">
<sentencetext>Available data from controlled clinical trials suggest that LABA as monotherapy increase the risk of asthma-related hospitalization in pediatric and adolescent patients.</sentencetext>
</sentence>
<sentence id="259" labeldrug="SEREVENT" section="34070-3">
<sentencetext>Use of SEREVENT DISKUS for the treatment of asthma without concomitant use of an ICS is contraindicated.</sentencetext>
</sentence>
<sentence id="260" labeldrug="SEREVENT" section="34070-3">
<sentencetext>The use of SEREVENT DISKUS is contraindicated in the following conditions: Primary treatment of status asthmaticus or other acute episodes of asthma or COPD where intensive measures are required Severe hypersensitivity to milk proteins or demonstrated hypersensitivity to salmeterol or any of the excipients Asthma: Without concomitant use of an ICS.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M13" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M14" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M15" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M16" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M17" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M18" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M19" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M110" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M111" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M112" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M113" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M114" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M115" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M116" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M117" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M118" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M119" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M120" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M121" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M122" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M123" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M124" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M125" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M126" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M127" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M128" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M129" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M130" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M131" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M132" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M133" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M134" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M135" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M136" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M137" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M138" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M139" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M140" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M141" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M142" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M143" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M144" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M145" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M146" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M147" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M148" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M149" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M150" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M151" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M152" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M153" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M154" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M155" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M156" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M157" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M158" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="261" labeldrug="SEREVENT" section="34070-3">
<sentencetext>Primary treatment of status asthmaticus or acute episodes of asthma or COPD requiring intensive measures.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M13" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M14" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M15" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M16" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M17" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M18" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M19" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M110" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M111" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M112" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M113" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M114" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M115" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M116" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="262" labeldrug="SEREVENT" section="34070-3">
<sentencetext>Severe hypersensitivity to milk proteins or demonstrated hypersensitivity to salmeterol or any of the excipients.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M13" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M14" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M15" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M16" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M17" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M18" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M19" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M110" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M111" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M112" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M113" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M114" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M115" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M116" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M12" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="263" labeldrug="SEREVENT" section="34068-7">
<sentencetext>SEREVENT DISKUS should be administered by the orally inhaled route only.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="264" labeldrug="SEREVENT" section="34068-7">
<sentencetext>More frequent administration or a greater number of inhalations (more than 1 inhalation twice daily) is not recommended as some patients are more likely to experience adverse effects.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="265" labeldrug="SEREVENT" section="34068-7">
<sentencetext>Patients using SEREVENT DISKUS should not use additional LABA for any reason.</sentencetext>
</sentence>
<sentence id="266" labeldrug="SEREVENT" section="34068-7">
<sentencetext>Treatment of asthma in patients aged 4 years and older: 1 inhalation twice daily in addition to concomitant treatment with an ICS.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M13" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M14" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M15" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M16" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M17" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M18" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M19" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M110" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M111" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M112" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M113" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M114" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M115" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M116" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M117" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M118" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M119" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M120" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M121" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M122" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M123" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M124" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="267" labeldrug="SEREVENT" section="34068-7">
<sentencetext>EIB: 1 inhalation at least 30 minutes before exercise.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M13" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M14" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M15" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M16" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M17" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M18" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M19" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M110" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M111" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M112" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="268" labeldrug="SEREVENT" section="34068-7">
<sentencetext>Maintenance treatment of bronchospasm associated with COPD: 1 inhalation twice daily.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="269" labeldrug="SEREVENT" section="34068-7">
<sentencetext>LABA, such as salmeterol, the active ingredient in SEREVENT DISKUS, as monotherapy (without ICS) increase the risk of asthma-related death.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="270" labeldrug="SEREVENT" section="34068-7">
<sentencetext>Because of this risk, use of SEREVENT DISKUS for the treatment of asthma without concomitant use of an ICS is contraindicated.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="271" labeldrug="SEREVENT" section="34068-7">
<sentencetext>For patients with asthma younger than 18 years who require addition of a LABA to an ICS, a fixed-dose combination product containing both an ICS and a LABA should ordinarily be used to ensure adherence with both drugs.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M13" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M12" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="272" labeldrug="SEREVENT" section="34068-7">
<sentencetext>In cases where use of a separate ICS and a LABA is clinically indicated, appropriate steps must be taken to ensure adherence with both treatment components.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M13" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M14" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M15" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="273" labeldrug="SEREVENT" section="34068-7">
<sentencetext>For bronchodilatation and prevention of symptoms of asthma, including the symptoms of nocturnal asthma, the usual dosage for adults and children aged 4 years and older is 1 inhalation (50 mcg) twice daily, approximately 12 hours apart.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M13" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M14" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M15" span="2 3" str="Hello" type="Trigger"></mention>
</sentence>
<sentence id="274" labeldrug="SEREVENT" section="34068-7">
<sentencetext>If a previously effective dosage regimen fails to provide the usual response, medical advice should be sought immediately as this is often a sign of destabilization of asthma.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="275" labeldrug="SEREVENT" section="34068-7">
<sentencetext>Under these circumstances, the therapeutic regimen should be reevaluated.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M13" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M14" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M15" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="276" labeldrug="SEREVENT" section="34068-7">
<sentencetext>If symptoms arise in the period between doses, an inhaled, short-acting beta2-agonist should be taken for immediate relief.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M12" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="277" labeldrug="SEREVENT" section="34068-7">
<sentencetext>Use of SEREVENT DISKUS as a single agent for the prevention of EIB may be clinically indicated in patients who do not have persistent asthma.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
</sentence>
<sentence id="278" labeldrug="SEREVENT" section="34068-7">
<sentencetext>In patients with persistent asthma, use of SEREVENT DISKUS for the prevention of EIB may be clinically indicated, but the treatment of asthma should include an ICS.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M13" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M14" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M15" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="279" labeldrug="SEREVENT" section="34068-7">
<sentencetext>One inhalation of SEREVENT DISKUS at least 30 minutes before exercise has been shown to protect patients against EIB.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M13" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="280" labeldrug="SEREVENT" section="34068-7">
<sentencetext>When used intermittently as needed for prevention of EIB, this protection may last up to 9 hours in adults and adolescents and up to 12 hours in patients aged 4 to 11 years.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="281" labeldrug="SEREVENT" section="34068-7">
<sentencetext>Additional doses of SEREVENT should not be used for 12 hours after the administration of this drug.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="282" labeldrug="SEREVENT" section="34068-7">
<sentencetext>Patients who are receiving SEREVENT DISKUS twice daily should not use additional SEREVENT for prevention of EIB.</sentencetext>
</sentence>
<sentence id="283" labeldrug="SEREVENT" section="34068-7">
<sentencetext>For maintenance treatment of bronchospasm associated with COPD (including chronic bronchitis and emphysema), the dosage for adults is 1 inhalation (50 mcg) twice daily approximately 12 hours apart.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M13" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="284" labeldrug="SEREVENT" section="34073-7">
<sentencetext>Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): Use not recommended.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M13" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M14" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="285" labeldrug="SEREVENT" section="34073-7">
<sentencetext>May increase risk of cardiovascular effects.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M13" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M14" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M15" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M16" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M17" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="286" labeldrug="SEREVENT" section="34073-7">
<sentencetext>Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M13" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M14" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M15" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M16" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M17" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M18" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M19" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M110" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M111" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M112" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="287" labeldrug="SEREVENT" section="34073-7">
<sentencetext>May potentiate effect of salmeterol on vascular system.</sentencetext>
</sentence>
<sentence id="288" labeldrug="SEREVENT" section="34073-7">
<sentencetext>Beta-blockers: Use with caution.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M13" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M14" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M15" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M16" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M17" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M18" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M19" span="2 3" str="Hello" type="Trigger"></mention>
</sentence>
<sentence id="289" labeldrug="SEREVENT" section="34073-7">
<sentencetext>May block bronchodilatory effects of beta-agonists and produce severe bronchospasm.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="290" labeldrug="SEREVENT" section="34073-7">
<sentencetext>Electrocardiographic changes and/or hypokalemia associated with non–potassium-sparing diuretics may worsen with concomitant beta-agonists.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M13" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="291" labeldrug="SEREVENT" section="34073-7">
<sentencetext>Salmeterol is a substrate of CYP3A4.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="292" labeldrug="SEREVENT" section="34073-7">
<sentencetext>The use of strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, ketoconazole, telithromycin) with SEREVENT DISKUS is not recommended because increased cardiovascular adverse effects may occur.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M13" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M14" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M12" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="293" labeldrug="SEREVENT" section="34073-7">
<sentencetext>In a drug interaction trial in 20 healthy subjects, coadministration of inhaled salmeterol (50 mcg twice daily) and oral ketoconazole (400 mg once daily) for 7 days resulted in greater systemic exposure to salmeterol (AUC increased 16-fold and Cmax increased 1.4-fold).</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="294" labeldrug="SEREVENT" section="34073-7">
<sentencetext>Three (3) subjects were withdrawn due to beta2-agonist side effects (2 with prolonged QTc and 1 with palpitations and sinus tachycardia).</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M12" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="295" labeldrug="SEREVENT" section="34073-7">
<sentencetext>Although there was no statistical effect on the mean QTc, coadministration of salmeterol and ketoconazole was associated with more frequent increases in QTc duration compared with salmeterol and placebo administration.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="296" labeldrug="SEREVENT" section="34073-7">
<sentencetext>SEREVENT DISKUS should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, because the action of salmeterol on the vascular system may be potentiated by these agents.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M12" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="297" labeldrug="SEREVENT" section="34073-7">
<sentencetext>Beta-blockers not only block the pulmonary effect of beta-agonists, such as salmeterol, but may also produce severe bronchospasm in patients with asthma or COPD.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M13" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="298" labeldrug="SEREVENT" section="34073-7">
<sentencetext>Therefore, patients with asthma or COPD should not normally be treated with beta-blockers.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M12" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="299" labeldrug="SEREVENT" section="34073-7">
<sentencetext>However, under certain circumstances, there may be no acceptable alternatives to the use of beta-adrenergic blocking agents for these patients; cardioselective beta-blockers could be considered, although they should be administered with caution.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M13" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M14" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M15" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M16" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="300" labeldrug="SEREVENT" section="34073-7">
<sentencetext>The ECG changes and/or hypokalemia that may result from the administration of non–potassium-sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="301" labeldrug="SEREVENT" section="34073-7">
<sentencetext>Although the clinical significance of these effects is not known, caution is advised in the coadministration of SEREVENT DISKUS with non–potassium-sparing diuretics.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M13" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="302" labeldrug="SEREVENT" section="43685-7">
<sentencetext>LABA as monotherapy (without ICS) for asthma increase the risk of asthma-related death and asthma-related hospitalizations.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="303" labeldrug="SEREVENT" section="43685-7">
<sentencetext>Prescribe for asthma only as concomitant therapy with an inhaled corticosteroid.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M13" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M14" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M15" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M16" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M17" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M18" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M19" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M110" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M111" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M112" span="2 3" str="Hello" type="Trigger"></mention>
</sentence>
<sentence id="304" labeldrug="SEREVENT" section="43685-7">
<sentencetext>Do not initiate in acutely deteriorating asthma or COPD.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M13" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M14" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M15" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M16" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M17" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M18" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M19" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="305" labeldrug="SEREVENT" section="43685-7">
<sentencetext>Not a substitute for corticosteroids.</sentencetext>
</sentence>
<sentence id="306" labeldrug="SEREVENT" section="43685-7">
<sentencetext>Patients with asthma must take a concomitant ICS.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
</sentence>
<sentence id="307" labeldrug="SEREVENT" section="43685-7">
<sentencetext>Do not use in combination with an additional medicine containing a LABA because of risk of overdose.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M13" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M14" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M15" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M16" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M17" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M18" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M19" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M110" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M111" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M112" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M113" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M114" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M115" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M116" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M117" span="2 3" str="Hello" type="Trigger"></mention>
</sentence>
<sentence id="308" labeldrug="SEREVENT" section="43685-7">
<sentencetext>If paradoxical bronchospasm occurs, discontinue SEREVENT DISKUS and institute alternative therapy.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="309" labeldrug="SEREVENT" section="43685-7">
<sentencetext>Use with caution in patients with cardiovascular or central nervous system disorders because of beta-adrenergic stimulation.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M13" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M14" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M15" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M16" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M17" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M18" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M19" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M110" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M111" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M112" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M113" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M114" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M115" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M116" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M117" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M118" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M119" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M120" span="2 3" str="Hello" type="Trigger"></mention>
</sentence>
<sentence id="310" labeldrug="SEREVENT" section="43685-7">
<sentencetext>Use with caution in patients with convulsive disorders, thyrotoxicosis, diabetes mellitus, and ketoacidosis.</sentencetext>
</sentence>
<sentence id="311" labeldrug="SEREVENT" section="43685-7">
<sentencetext>Be alert to hypokalemia and hyperglycemia.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M13" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M14" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M15" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M16" span="2 3" str="Hello" type="Trigger"></mention>
</sentence>
<sentence id="312" labeldrug="SEREVENT" section="43685-7">
<sentencetext>When LABA are used in fixed‑dose combination with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared with ICS alone.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
</sentence>
<sentence id="313" labeldrug="SEREVENT" section="43685-7">
<sentencetext>The Salmeterol Multicenter Asthma Research Trial (SMART) was a large 28-week placebo-controlled U.S. trial comparing the safety of salmeterol (SEREVENT Inhalation Aerosol) with placebo, each added to usual asthma therapy, that showed an increase in asthma-related deaths in subjects receiving salmeterol.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M13" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="314" labeldrug="SEREVENT" section="43685-7">
<sentencetext>Given the similar basic mechanisms of action of beta2-agonists, the findings seen in the SMART trial are considered a class effect.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M13" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="315" labeldrug="SEREVENT" section="43685-7">
<sentencetext>A 16-week clinical trial performed in the United Kingdom, the Salmeterol Nationwide Surveillance (SNS) trial, showed results similar to the SMART trial.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
</sentence>
<sentence id="316" labeldrug="SEREVENT" section="43685-7">
<sentencetext>In the SNS trial, the rate of asthma-related death was numerically, though not statistically significantly, greater in subjects with asthma treated with salmeterol (42 mcg twice daily) than those treated with albuterol (180 mcg 4 times daily) added to usual asthma therapy.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="317" labeldrug="SEREVENT" section="43685-7">
<sentencetext>The SNS and SMART trials enrolled subjects with asthma.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="318" labeldrug="SEREVENT" section="43685-7">
<sentencetext>Available data do not suggest an increased risk of death with use of LABA in patients with COPD.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
</sentence>
<sentence id="319" labeldrug="SEREVENT" section="43685-7">
<sentencetext>SEREVENT DISKUS should not be initiated in patients during rapidly deteriorating or potentially life-threatening episodes of asthma or COPD.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M12" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M13" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M14" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M15" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="320" labeldrug="SEREVENT" section="43685-7">
<sentencetext>SEREVENT DISKUS has not been studied in subjects with acutely deteriorating asthma or COPD.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="321" labeldrug="SEREVENT" section="43685-7">
<sentencetext>The initiation of SEREVENT DISKUS in this setting is not appropriate.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M13" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M14" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="322" labeldrug="SEREVENT" section="43685-7">
<sentencetext>Serious acute respiratory events, including fatalities, have been reported when salmeterol has been initiated in patients with significantly worsening or acutely deteriorating asthma.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="323" labeldrug="SEREVENT" section="43685-7">
<sentencetext>In most cases, these have occurred in patients with severe asthma (e.g., patients with a history of corticosteroid dependence, low pulmonary function, intubation, mechanical ventilation, frequent hospitalizations, previous life-threatening acute asthma exacerbations) and in some patients with acutely deteriorating asthma (e.g., patients with significantly increasing symptoms; increasing need for inhaled, short-acting beta2-agonists; decreasing response to usual medications; increasing need for systemic corticosteroids; recent emergency room visits; deteriorating lung function).</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M13" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M14" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M15" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M16" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M17" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M18" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M19" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M12" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M13" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M14" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M15" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="324" labeldrug="SEREVENT" section="43685-7">
<sentencetext>However, these events have occurred in a few patients with less severe asthma as well.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="325" labeldrug="SEREVENT" section="43685-7">
<sentencetext>It was not possible from these reports to determine whether salmeterol contributed to these events.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M12" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="326" labeldrug="SEREVENT" section="43685-7">
<sentencetext>Increasing use of inhaled, short-acting beta2-agonists is a marker of deteriorating asthma.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="327" labeldrug="SEREVENT" section="43685-7">
<sentencetext>In this situation, the patient requires immediate reevaluation with reassessment of the treatment regimen, giving special consideration to the possible need for adding additional ICS or initiating systemic corticosteroids.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M13" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M14" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M15" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="328" labeldrug="SEREVENT" section="43685-7">
<sentencetext>Patients should not use more than 1 inhalation twice daily of SEREVENT DISKUS.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M13" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M14" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M15" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M16" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M17" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M18" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M19" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M110" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M111" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M112" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M113" span="2 3" str="Hello" type="Trigger"></mention>
</sentence>
<sentence id="329" labeldrug="SEREVENT" section="43685-7">
<sentencetext>SEREVENT DISKUS should not be used for the relief of acute symptoms, i.e., as rescue therapy for the treatment of acute episodes of bronchospasm.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M13" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M14" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M15" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="330" labeldrug="SEREVENT" section="43685-7">
<sentencetext>An inhaled, short-acting beta2-agonist, not SEREVENT DISKUS, should be used to relieve acute symptoms such as shortness of breath.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
</sentence>
<sentence id="331" labeldrug="SEREVENT" section="43685-7">
<sentencetext>When prescribing SEREVENT DISKUS, the healthcare provider should also prescribe an inhaled, short-acting beta2-agonist (e.g., albuterol) for treatment of acute symptoms.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M13" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="332" labeldrug="SEREVENT" section="43685-7">
<sentencetext>When beginning treatment with SEREVENT DISKUS, patients who have been taking oral or inhaled, short-acting beta2-agonists on a regular basis (e.g., 4 times a day) should be instructed to discontinue the regular use of these drugs.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M13" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M12" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="333" labeldrug="SEREVENT" section="43685-7">
<sentencetext>There are no data demonstrating that SEREVENT DISKUS has a clinical anti-inflammatory effect such as that associated with corticosteroids.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="334" labeldrug="SEREVENT" section="43685-7">
<sentencetext>When initiating and throughout treatment with SEREVENT DISKUS in patients receiving oral or ICS for treatment of asthma, patients must continue taking a suitable dosage of corticosteroids to maintain clinical stability even if they feel better as a result of initiating SEREVENT DISKUS.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="335" labeldrug="SEREVENT" section="43685-7">
<sentencetext>Any change in corticosteroid dosage should be made ONLY after clinical evaluation.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="336" labeldrug="SEREVENT" section="43685-7">
<sentencetext>SEREVENT DISKUS should not be used more often than recommended, at higher doses than recommended, or in conjunction with other medicines containing LABA, as an overdose may result.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="337" labeldrug="SEREVENT" section="43685-7">
<sentencetext>Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="338" labeldrug="SEREVENT" section="43685-7">
<sentencetext>Patients using SEREVENT DISKUS should not use another medicine containing a LABA (e.g., formoterol fumarate, arformoterol tartrate, indacaterol) for any reason.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M13" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M14" span="2 3" str="Hello" type="Trigger"></mention>
</sentence>
<sentence id="339" labeldrug="SEREVENT" section="43685-7">
<sentencetext>As with other inhaled medicines, SEREVENT DISKUS can produce paradoxical bronchospasm, which may be life threatening.</sentencetext>
</sentence>
<sentence id="340" labeldrug="SEREVENT" section="43685-7">
<sentencetext>If paradoxical bronchospasm occurs following dosing with SEREVENT DISKUS, it should be treated immediately with an inhaled, short-acting bronchodilator; SEREVENT DISKUS should be discontinued immediately; and alternative therapy should be instituted.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="341" labeldrug="SEREVENT" section="43685-7">
<sentencetext>Upper airway symptoms of laryngeal spasm, irritation, or swelling, such as stridor and choking, have been reported in patients receiving SEREVENT DISKUS.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="342" labeldrug="SEREVENT" section="43685-7">
<sentencetext>Excessive beta-adrenergic stimulation has been associated with seizures, angina, hypertension or hypotension, tachycardia with rates up to 200 beats/min, arrhythmias, nervousness, headache, tremor, palpitation, nausea, dizziness, fatigue, malaise, and insomnia.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M13" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M12" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="343" labeldrug="SEREVENT" section="43685-7">
<sentencetext>Therefore, SEREVENT DISKUS, like all products containing sympathomimetic amines, should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="344" labeldrug="SEREVENT" section="43685-7">
<sentencetext>Salmeterol can produce a clinically significant cardiovascular effect in some patients as measured by pulse rate, blood pressure, and/or symptoms.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M13" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="345" labeldrug="SEREVENT" section="43685-7">
<sentencetext>Although such effects are uncommon after administration of salmeterol at recommended doses, if they occur, the drug may need to be discontinued.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M13" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="346" labeldrug="SEREVENT" section="43685-7">
<sentencetext>In addition, beta-agonists have been reported to produce electrocardiogram (ECG) changes, such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="347" labeldrug="SEREVENT" section="43685-7">
<sentencetext>The clinical significance of these findings is unknown.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="348" labeldrug="SEREVENT" section="43685-7">
<sentencetext>Large doses of inhaled or oral salmeterol (12 to 20 times the recommended dose) have been associated with clinically significant prolongation of the QTc interval, which has the potential for producing ventricular arrhythmias.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M12" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="349" labeldrug="SEREVENT" section="43685-7">
<sentencetext>Fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="350" labeldrug="SEREVENT" section="43685-7">
<sentencetext>Immediate hypersensitivity reactions (e.g., urticaria, angioedema, rash, bronchospasm, hypotension), including anaphylaxis, may occur after administration of SEREVENT DISKUS.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="351" labeldrug="SEREVENT" section="43685-7">
<sentencetext>There have been reports of anaphylactic reactions in patients with severe milk protein allergy after inhalation of powder products containing lactose; therefore, patients with severe milk protein allergy should not use SEREVENT DISKUS.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="352" labeldrug="SEREVENT" section="43685-7">
<sentencetext>The use of strong cytochrome P450 3A4 (CYP3A4) inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, ketoconazole, telithromycin) with SEREVENT DISKUS is not recommended because increased cardiovascular adverse effects may occur.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M13" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M14" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M15" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M16" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M17" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M12" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="353" labeldrug="SEREVENT" section="43685-7">
<sentencetext>SEREVENT DISKUS, like all medicines containing sympathomimetic amines, should be used with caution in patients with convulsive disorders or thyrotoxicosis and in those who are unusually responsive to sympathomimetic amines.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="354" labeldrug="SEREVENT" section="43685-7">
<sentencetext>Doses of the related beta2-adrenoceptor agonist albuterol, when administered intravenously, have been reported to aggravate preexisting diabetes mellitus and ketoacidosis.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="355" labeldrug="SEREVENT" section="43685-7">
<sentencetext>Beta-adrenergic agonist medicines may produce significant hypokalemia in some patients, possibly through intracellular shunting, which has the potential to produce adverse cardiovascular effects.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M13" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="356" labeldrug="SEREVENT" section="43685-7">
<sentencetext>The decrease in serum potassium is usually transient, not requiring supplementation.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="357" labeldrug="SEREVENT" section="43685-7">
<sentencetext>Clinically significant and dose-related changes in blood glucose and/or serum potassium were seen infrequently during clinical trials with SEREVENT DISKUS at recommended doses.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="358" labeldrug="SEREVENT" section="34090-1">
<sentencetext>In vitro studies show salmeterol to be at least 50 times more selective for beta2-adrenoceptors than albuterol.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M12" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="359" labeldrug="SEREVENT" section="34090-1">
<sentencetext>Although beta2-adrenoceptors are the predominant adrenergic receptors in bronchial smooth muscle and beta1-adrenoceptors are the predominant receptors in the heart, there are also beta2-adrenoceptors in the human heart comprising 10% to 50% of the total beta-adrenoceptors.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M13" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M14" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M15" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M16" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="360" labeldrug="SEREVENT" section="34090-1">
<sentencetext>The precise function of these receptors has not been established, but their presence raises the possibility that even selective beta2-agonists may have cardiac effects.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="361" labeldrug="SEREVENT" section="34090-1">
<sentencetext>The pharmacologic effects of beta2-adrenoceptor agonist drugs, including salmeterol, are at least in part attributable to stimulation of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3′,5′-adenosine monophosphate (cyclic AMP).</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M12" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="362" labeldrug="SEREVENT" section="34090-1">
<sentencetext>Increased cyclic AMP levels cause relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M13" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M14" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M12" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="363" labeldrug="SEREVENT" section="34090-1">
<sentencetext>In vitro tests show that salmeterol is a potent and long-lasting inhibitor of the release of mast cell mediators, such as histamine, leukotrienes, and prostaglandin D2, from human lung.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M12" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="364" labeldrug="SEREVENT" section="34090-1">
<sentencetext>Salmeterol inhibits histamine-induced plasma protein extravasation and inhibits platelet-activating factor–induced eosinophil accumulation in the lungs of guinea pigs when administered by the inhaled route.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M13" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M14" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M15" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M12" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="365" labeldrug="SEREVENT" section="34090-1">
<sentencetext>In humans, single doses of salmeterol administered via inhalation aerosol attenuate allergen-induced bronchial hyper-responsiveness.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M12" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="366" labeldrug="SEREVENT" section="34090-1">
<sentencetext>Inhaled salmeterol, like other beta-adrenergic agonist drugs, can produce dose-related cardiovascular effects and effects on blood glucose and/or serum potassium.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="367" labeldrug="SEREVENT" section="34090-1">
<sentencetext>The cardiovascular effects (heart rate, blood pressure) associated with salmeterol inhalation aerosol occur with similar frequency, and are of similar type and severity, as those noted following albuterol administration.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M12" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="368" labeldrug="SEREVENT" section="34090-1">
<sentencetext>The effects of rising inhaled doses of salmeterol and standard inhaled doses of albuterol were studied in volunteers and in subjects with asthma.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="369" labeldrug="SEREVENT" section="34090-1">
<sentencetext>Salmeterol doses up to 84 mcg administered as inhalation aerosol resulted in heart rate increases of 3 to 16 beats/min, about the same as albuterol dosed at 180 mcg by inhalation aerosol (4 to 10 beats/min).</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M12" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="370" labeldrug="SEREVENT" section="34090-1">
<sentencetext>Adult and adolescent subjects receiving 50-mcg doses of salmeterol inhalation powder (n = 60) underwent continuous electrocardiographic monitoring during two 12-hour periods after the first dose and after 1 month of therapy, and no clinically significant dysrhythmias were noted.</sentencetext>
</sentence>
<sentence id="371" labeldrug="SEREVENT" section="34090-1">
<sentencetext>Also, pediatric patients receiving 50-mcg doses of salmeterol inhalation powder (n = 67) underwent continuous electrocardiographic monitoring during two 12-hour periods after the first dose and after 3 months of therapy, and no clinically significant dysrhythmias were noted.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="372" labeldrug="SEREVENT" section="34090-1">
<sentencetext>In 24-week clinical studies in patients with COPD, the incidence of clinically significant abnormalities on the predose ECGs at Weeks 12 and 24 in patients who received salmeterol 50 mcg was not different compared with placebo.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M12" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="373" labeldrug="SEREVENT" section="34090-1">
<sentencetext>No effect of treatment with salmeterol 50 mcg was observed on pulse rate and systolic and diastolic blood pressure in a subset of patients with COPD who underwent 12-hour serial vital sign measurements after the first dose (n = 91) and after 12 weeks of therapy (n = 74).</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M12" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="374" labeldrug="SEREVENT" section="34090-1">
<sentencetext>Median changes from baseline in pulse rate and systolic and diastolic blood pressure were similar for patients receiving either salmeterol or placebo.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="375" labeldrug="SEREVENT" section="34090-1">
<sentencetext>Concomitant Use of SEREVENT DISKUS with Other Respiratory Medications Short-acting Beta2-agonists: In two 12-week repetitive-dose clinical trials in adult and adolescent subjects with asthma (N = 149), the mean daily need for additional beta2-agonist in subjects using SEREVENT DISKUS was approximately 1½ inhalations/day.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="376" labeldrug="SEREVENT" section="34090-1">
<sentencetext>Twenty-six percent (26%) of the subjects in these trials used between 8 and 24 inhalations of short-acting beta-agonist per day on 1 or more occasions.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="377" labeldrug="SEREVENT" section="34090-1">
<sentencetext>Nine percent (9%) of the subjects in these trials averaged over 4 inhalations/day over the course of the 12-week trials.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="378" labeldrug="SEREVENT" section="34090-1">
<sentencetext>No increase in frequency of cardiovascular events was observed among the 3 subjects who averaged 8 to 11 inhalations/day; however, the safety of concomitant use of more than 8 inhalations/day of short-acting beta2-agonist with SEREVENT DISKUS has not been established.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="379" labeldrug="SEREVENT" section="34090-1">
<sentencetext>In 29 subjects who experienced worsening of asthma while receiving SEREVENT DISKUS during these trials, albuterol therapy administered via either nebulizer or inhalation aerosol (1 dose in most cases) led to improvement in FEV1 and no increase in occurrence of cardiovascular adverse events.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
</sentence>
<sentence id="380" labeldrug="SEREVENT" section="34090-1">
<sentencetext>In 2 clinical trials in subjects with COPD, the mean daily need for additional beta2-agonist for subjects using SEREVENT DISKUS was approximately 4 inhalations/day.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M12" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="381" labeldrug="SEREVENT" section="34090-1">
<sentencetext>Twenty-four percent (24%) of subjects using SEREVENT DISKUS averaged 6 or more inhalations of albuterol per day over the course of the 24-week trials.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="382" labeldrug="SEREVENT" section="34090-1">
<sentencetext>No increase in frequency of cardiovascular adverse reactions was observed among subjects who averaged 6 or more inhalations per day.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="383" labeldrug="SEREVENT" section="34090-1">
<sentencetext>Methylxanthines: The concurrent use of intravenously or orally administered methylxanthines (e.g., aminophylline, theophylline) by subjects receiving salmeterol has not been completely evaluated.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
</sentence>
<sentence id="384" labeldrug="SEREVENT" section="34090-1">
<sentencetext>In 1 clinical trial in subjects with asthma, 87 subjects receiving SEREVENT Inhalation Aerosol 42 mcg twice daily concurrently with a theophylline product had adverse event rates similar to those in 71 subjects receiving SEREVENT Inhalation Aerosol without theophylline.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M12" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="385" labeldrug="SEREVENT" section="34090-1">
<sentencetext>Resting heart rates were slightly higher in the subjects on theophylline but were little affected by therapy with SEREVENT Inhalation Aerosol.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="386" labeldrug="SEREVENT" section="34090-1">
<sentencetext>In 2 clinical trials in subjects with COPD, 39 subjects receiving SEREVENT DISKUS concurrently with a theophylline product had adverse event rates similar to those in 302 subjects receiving SEREVENT DISKUS without theophylline.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="387" labeldrug="SEREVENT" section="34090-1">
<sentencetext>Based on the available data, the concomitant administration of methylxanthines with SEREVENT DISKUS did not alter the observed adverse event profile.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="388" labeldrug="SEREVENT" section="34090-1">
<sentencetext>Cromoglycate: In clinical trials, inhaled cromolyn sodium did not alter the safety profile of salmeterol when administered concurrently.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="389" labeldrug="SEREVENT" section="34090-1">
<sentencetext>Salmeterol xinafoate, an ionic salt, dissociates in solution so that the salmeterol and 1-hydroxy-2-naphthoic acid (xinafoate) moieties are absorbed, distributed, metabolized, and eliminated independently.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M13" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M14" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M15" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="390" labeldrug="SEREVENT" section="34090-1">
<sentencetext>Salmeterol acts locally in the lung; therefore, plasma levels do not predict therapeutic effect.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="391" labeldrug="SEREVENT" section="34090-1">
<sentencetext>Absorption Because of the small therapeutic dose, systemic levels of salmeterol are low or undetectable after inhalation of recommended doses (50 mcg of salmeterol inhalation powder twice daily).</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M13" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M14" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="392" labeldrug="SEREVENT" section="34090-1">
<sentencetext>Following chronic administration of an inhaled dose of 50 mcg of salmeterol inhalation powder twice daily, salmeterol was detected in plasma within 5 to 45 minutes in 7 subjects with asthma; plasma concentrations were very low, with mean peak concentrations of 167 pg/mL at 20 minutes and no accumulation with repeated doses.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="393" labeldrug="SEREVENT" section="34090-1">
<sentencetext>Distribution The percentage of salmeterol bound to human plasma proteins averages 96% in vitro over the concentration range of 8 to 7,722 ng of salmeterol base per milliliter, much higher concentrations than those achieved following therapeutic doses of salmeterol.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M13" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="394" labeldrug="SEREVENT" section="34090-1">
<sentencetext>Metabolism Salmeterol base is extensively metabolized by hydroxylation, with subsequent elimination predominantly in the feces.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M12" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="395" labeldrug="SEREVENT" section="34090-1">
<sentencetext>No significant amount of unchanged salmeterol base was detected in either urine or feces.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="396" labeldrug="SEREVENT" section="34090-1">
<sentencetext>An in vitro study using human liver microsomes showed that salmeterol is extensively metabolized to α-hydroxysalmeterol (aliphatic oxidation) by CYP3A4.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
</sentence>
<sentence id="397" labeldrug="SEREVENT" section="34090-1">
<sentencetext>Ketoconazole, a strong inhibitor of CYP3A4, essentially completely inhibited the formation of α-hydroxysalmeterol in vitro.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="398" labeldrug="SEREVENT" section="34090-1">
<sentencetext>Elimination In 2 healthy adult subjects who received 1 mg of radiolabeled salmeterol (as salmeterol xinafoate) orally, approximately 25% and 60% of the radiolabeled salmeterol was eliminated in urine and feces, respectively, over a period of 7 days.</sentencetext>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M12" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="399" labeldrug="SEREVENT" section="34090-1">
<sentencetext>The terminal elimination half-life was about 5.5 hours (1 volunteer only).</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="400" labeldrug="SEREVENT" section="34090-1">
<sentencetext>The xinafoate moiety has no apparent pharmacologic activity.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="401" labeldrug="SEREVENT" section="34090-1">
<sentencetext>The xinafoate moiety is highly protein bound (&gt;99%) and has a long elimination half-life of 11 days.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M13" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="402" labeldrug="SEREVENT" section="34090-1">
<sentencetext>Drug Interaction Studies Inhibitors of Cytochrome P450 3A4: Ketoconazole: In a placebo-controlled crossover drug interaction trial in 20 healthy male and female subjects, coadministration of salmeterol (50 mcg twice daily) and the strong CYP3A4 inhibitor ketoconazole (400 mg once daily) for 7 days resulted in a significant increase in plasma salmeterol exposure as determined by a 16-fold increase in AUC (ratio with and without ketoconazole 15.76 [90% CI: 10.66, 23.31]) mainly due to increased bioavailability of the swallowed portion of the dose.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M12" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M13" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M14" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="403" labeldrug="SEREVENT" section="34090-1">
<sentencetext>Peak plasma salmeterol concentrations were increased by 1.4-fold (90% CI: 1.23, 1.68).</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="404" labeldrug="SEREVENT" section="34090-1">
<sentencetext>Three (3) out of 20 subjects (15%) were withdrawn from salmeterol and ketoconazole coadministration due to beta-agonist–mediated systemic effects (2 with QTc prolongation and 1 with palpitations and sinus tachycardia).</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M12" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M13" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="405" labeldrug="SEREVENT" section="34090-1">
<sentencetext>Coadministration of salmeterol and ketoconazole did not result in a clinically significant effect on mean heart rate, mean blood potassium, or mean blood glucose.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="406" labeldrug="SEREVENT" section="34090-1">
<sentencetext>Erythromycin: In a repeat-dose trial in 13 healthy subjects, concomitant administration of erythromycin (a moderate CYP3A4 inhibitor) and salmeterol inhalation aerosol resulted in a 40% increase in salmeterol Cmax at steady state (ratio with and without erythromycin 1.4 [90% CI: 0.96, 2.03], P = 0.12), a 3.6-beat/min increase in heart rate ([95% CI: 0.19, 7.03], P&lt;0.04), a 5.8-msec increase in QTc interval ([95% CI: -6.14, 17.77], P = 0.34), and no change in plasma potassium.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M13" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M14" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M15" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M12" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M13" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M14" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M15" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="406" labeldrug="SEREVENT" section="34090-1">
<sentencetext>Erythromycin: In a repeat-dose trial in 13 healthy subjects, concomitant administration of erythromycin (a moderate CYP3A4 inhibitor) and salmeterol inhalation aerosol resulted in a 40% increase in salmeterol Cmax at steady state (ratio with and without erythromycin 1.4 [90% CI: 0.96, 2.03], P = 0.12), a 3.6-beat/min increase in heart rate ([95% CI: 0.19, 7.03], P&lt;0.04), a 5.8-msec increase in QTc interval ([95% CI: -6.14, 17.77], P = 0.34), and no change in plasma potassium.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M13" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M14" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M15" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M16" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M17" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M18" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M19" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M110" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M111" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M112" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M113" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M114" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M115" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M116" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M117" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M118" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M119" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M120" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M121" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M122" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M123" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M124" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M125" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M126" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M127" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M128" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M129" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M130" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M131" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M132" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M133" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M134" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M135" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M136" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M137" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M138" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M139" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M140" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M141" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M142" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M143" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M144" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M145" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M146" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M147" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M148" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M149" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M150" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M13" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M14" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M15" span="2 3" str="Hello" type="Trigger"></mention>
<Mention id="M11" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M12" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M13" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M14" span="2 3" str="Hello" type="Trigger"></Mention>
<Mention id="M15" span="2 3" str="Hello" type="Trigger"></Mention>
</sentence>
<sentence id="248" labeldrug="SEREVENT" section="34066-1">
<sentencetext>Use of SEREVENT DISKUS for the treatment of asthma as monotherapy without a concomitant ICS is contraindicated.</sentencetext>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M13" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M14" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M15" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M16" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M17" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M18" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M19" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M11" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M12" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M13" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M14" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M15" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M16" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M17" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M18" span="2 3" str="Hello" type="Trigger"></mention>
<mention id="M19" span="2 3" str="Hello" type="Trigger"></mention>
</sentence>
